FGF21, fibroblast growth factor 21, 26291

N. diseases: 236; N. variants: 2
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.100 AlteredExpression group BEFREE Induction of diabetes increased FGF21 levels and both of the treatments could reduce its contents, however, glibenclamide was more effective than HESS. 31655149 2020
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.100 AlteredExpression group BEFREE Multivariate analysis showed that FGF-21 level was associated with hepatic steatosis (OR 1.005, 95% CI 1.001-1.009) and F3/F4 (OR 0.993, 95% CI 0.989-0.998), while AFABP level (OR 1.001, 95% CI 1-1.002), body mass index (BMI) (OR 1.107, 95% CI 1.037-1.182) and presence of diabetes mellitus (OR 2.059, 95% CI 1.206-3.516) were associated with F3/F4. 30912255 2019
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.100 Biomarker group BEFREE Fibroblast growth factor 21 (FGF21) is closely linked with metabolic disorders including diabetes. 31205953 2019
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.100 Biomarker group BEFREE Fibroblast growth factor 21 (FGF21) is a potential diabetic drug, however, it has not been investigated whether FGF21 prevents neointima hyperplasia in DM. 31513948 2019
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.100 AlteredExpression group BEFREE Higher levels of FGF21 were expressed, particularly in patients with diabetes. 30959789 2019
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.100 AlteredExpression group BEFREE Female gender, hypertension, systolic blood pressure (SBP), diastolic blood pressure (DBP), waist circumference (WC), body weight (BW), body mass index (BMI), body fat mass, fasting glucose, glycated hemoglobin level (HbA1c), triglyceride level (TG), urine albumin-to-creatinine ratio (UACR), insulin level, homeostasis model assessment of insulin resistance (HOMA-IR), and FGF21 levels were higher, whereas high-density lipoprotein cholesterol level (HDL-C) and estimated glomerular filtration rate (eGFR) were lower in DM patients with MetS. 31582974 2019
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.100 Biomarker group BEFREE FGF21 acts mainly on adipose tissue and ectopic fat accumulation is a typical feature in metabolic deterioration such as diabetes, metabolic syndrome, and cardiovascular disease. 31798902 2019
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.100 Biomarker group BEFREE Recently, a member of the fibroblast growth factor (FGF) superfamily, FGF21 has proved tremendous efficacy in diseases like diabetes mellitus, obesity and insulin resistance (IR). 31333086 2019
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.100 AlteredExpression group BEFREE Thus, we aim to examine whether FGF-21 regulates expression of intestinal SGLT1 in diabetes. 30551357 2019
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.100 Biomarker group BEFREE Our aims were to examine the add-on effects of a sodium-glucose cotransporter 2 inhibitor, dapagliflozin, compared with existing antidiabetes treatments, on anthropometric/metabolic parameters, the levels of an endocrine regulator, fibroblast growth factor 21 (FGF21); a skeletal muscle mass (SMM) negative regulator, myostatin; and a metabolic regulator, irisin, in patients with type 2 diabetes. 31721467 2019
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.100 Biomarker group BEFREE Previous studies showed that FGF21 ameliorated and prevented the development of metabolic disorders, such as obesity and diabetes mellitus. 30991048 2019
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.100 Biomarker group BEFREE Fibroblast growth factor 21 (FGF-21) is an important regulator in glycolipid metabolism that is a promising drug candidate for treatment of diabetes and obesity. 31129207 2019
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.100 Biomarker group BEFREE Previous studies have indicated that fibroblast growth factor 21 (FGF21), an attractive and potential therapeutic treatment for DM, may exert diverse effects in the central nervous system. 30785085 2019
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.100 Biomarker group BEFREE This review summarizes studies of the possible involvement of dietary methionine restriction in improving insulin resistance, glucose homeostasis, oxidative stress, lipid metabolism, the pentose phosphate pathway (PPP), and inflammation, with an emphasis on the fibroblast growth factor 21 and protein phosphatase 2A signals and autophagy in diabetes. 29603632 2018
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.100 Biomarker group BEFREE We assessed whether plasma concentrations of three known myokines [myonectin, myostatin, and fibroblast-derived growth factor 21 (FGF-21)] would be associated with direct and indirect indicators of insulin resistance (IR) in individuals who did not have a diagnosis of diabetes. 29445355 2018
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.100 AlteredExpression group BEFREE Thus, in contrast to what is observed in obesity and diabetes, high levels of FGF21 in healthy aging are not associated with repressed FGF21-responsiveness machinery in adipose tissue. 30043445 2018
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.100 Biomarker group BEFREE HDAC3 inhibition in diabetic mice may activate Nrf2 preventing diabetes-induced liver damage and FGF21 synthesis and secretion leading to aortic protection. 29634312 2018
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.100 Biomarker group BEFREE Numerous studies have been conducted to establish and confirm whether FGF21 exerts beneficial effects on obesity and diabetes along with its complications. 29989062 2018
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.100 Biomarker group BEFREE Recently, FGF-21 was found to have anti-inflammatory effect, to our knowledge, the effect of FGF-21 on inflammatory state in diabetes has not been elucidated. 29414665 2018
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.100 AlteredExpression group BEFREE Circulating FGF21 level was independently associated with CIN (aOR: 4.66, 95% CI: 1.29-16.86, p = 0.019) and renal function decline (aHR: 7.98, 95% CI: 4.07-15.66, p < 0.001) whether diabetes was present or not. 30127382 2018
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.100 Biomarker group BEFREE During the past decade, there has been an enormous effort made to understand the physiological roles of FGF21 in regulating metabolism and to identify the mechanism for its potent pharmacological effects to reverse diabetes and obesity. 29727594 2018
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.100 Biomarker group BEFREE Thus, hepatic TTP posttranscriptionally regulates systemic insulin sensitivity in diabetes through liver-derived FGF21. 29997282 2018
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.100 Biomarker group BEFREE Metallothionein can modulate various stress-induced signaling pathways (mitogen-activated protein kinase, Wnt, nuclear factor-κB, phosphatidylinositol 3-kinase, sirtuin 1/AMP-activated protein kinase and fibroblast growth factor 21) to alleviate diabetes and diabetic complications. 29072367 2018
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.100 GeneticVariation group BEFREE This is in contrast to the anti-diabetic medication metformin and suggests that the treatment of obesity and diabetes with the combination of FGF21 and AMPK activators merits consideration. 28580278 2017
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.100 Biomarker group BEFREE FGF21 had the best change in log likelihood when added to a diabetes prediction model (DP) based on age, family history, smoking, hypertension, BMI, dyslipidaemia and FG. 27611701 2017